Background {#Sec1}
==========

Digestive system malignancies such as liver cancer, gastric cancer, and colorectal cancer are leading types of cancer among both males and females \[[@CR1], [@CR2]\]. Although their definite pathogenesis mechanisms are still unclear, accumulating evidence suggests that genetic architecture plays vital roles in their development. Firstly, the incidences of digestive system malignancies have been found to be higher in subjects with positive family history in first-degree relatives \[[@CR3]--[@CR5]\], and genetic background is probably one of the reasons behind this phenomenon. Secondly, previous genetic association studies have also detected numerous susceptible genetic loci of digestive system malignancies in different populations \[[@CR6]--[@CR8]\]. However, the pathogenesis mechanisms of digestive system malignancies are very complicated, and genetic factors that contribute to the development of digestive system malignancies still require intensive explorations.

Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) serves as a negative regulator of immune responses and is essential for modulating anti-tumor immune responses \[[@CR9], [@CR10]\]. So, if a polymorphism is of potential functional significance and can impact the gene expression or protein structure of CTLA-4, it is likely that this polymorphism might also influence predisposition to many types of malignant diseases including digestive system malignancies.

In the last two decades, investigators across the world have extensively explored the relationship between *CTLA-4* polymorphisms and digestive system malignancies, yet the relationships between *CTLA-4* polymorphisms and digestive system malignancies are still controversial and ambiguous. Thus, the authors designed this meta-analysis to get a more statistically reliable conclusion regarding the relationships between *CTLA-4* polymorphisms and digestive system malignancies by pooling the results of related studies.

Methods {#Sec2}
=======

The PRISMA guideline was followed by the authors when conducting this meta-analysis \[[@CR11]\].

Literature search and inclusion criteria {#Sec3}
----------------------------------------

Literature searching of PubMed, Web of Science, Embase, and CNKI was performed by the authors using the following terms: (Cytotoxic T lymphocyte antigen-4 or CTLA-4) and (polymorphism or variant or variation or mutation or SNP or genome-wide association study or genetic association study or genotype or allele) and (colorectal or colon or rectal or pancreatic or pancreas or esophageal or esophagus or gastric or stomach or liver or hepatic) and (cancer or tumor or carcinoma or neoplasm or malignancy). The authors also checked the references of retrieved articles for additional related studies.

Eligible studies must meet all of the three inclusion criteria: (I) formally published case-control studies evaluating relationships between *CTLA-4* polymorphisms and digestive system malignancies, (II) provide genotypic distributions of *CTLA-4* polymorphisms in patients with digestive system malignancies and controls, and (III) the full manuscript is available in English or Chinese. Articles were excluded if at least one of the following three conditions was fulfilled: (I) studies not concerning *CTLA-4* polymorphisms and digestive system malignancies, (II) reviews or expert comments, and (III) case series that only involved patients with digestive system malignancies. When duplicate reports were observed during literature searching, only the most complete one was included for pooled analyses.

Data extraction and quality assessment {#Sec4}
--------------------------------------

We extracted the following items from eligible studies: (I) surname of the first author, (II) year of online publication, (III) country and ethnicity of involved subjects, (IV) number of patients and controls in each study, and (V) genotypic distributions of *CTLA-4* polymorphisms in patients and control subjects. We also calculated the *p* values of Hardy-Weinberg equilibrium (HWE) based on genotypic distributions of *CTLA-4* polymorphisms.

The authors used the Newcastle-Ottawa scale (NOS) to assess the quality of included studies \[[@CR12]\]. The score range of NOS is from zero to nine, and the methodology quality of a study is considered to be good if it can get a score of more than seven.

Data extraction and quality assessment of eligible studies were performed by two authors separately. We would write to the corresponding authors of eligible studies for additional data if we fail to extract necessary information from included studies.

Statistical analyses {#Sec5}
--------------------

The authors used Review Manager to pool the results of eligible studies. The authors used *Z* test to evaluate the relationships between *CTLA-4* polymorphisms and predisposition to digestive system malignancies. The authors set the statistical significant threshold at 0.05. We compared genetic distributions of *CTLA-4* polymorphisms among cases and controls in dominant, recessive, over-dominant, and allele models; the dominant genetic model is defined as M/M vs. M/m + m/m, recessive genetic model is defined as m/m vs. M/M + M/m, over-dominant genetic model is defined as M/m vs. M/M + m/m, and the allele genetic model is defined as M vs. m. The authors used *I*^2^ statistics to estimate heterogeneity. The authors used the DerSimonian-Laird method to pool the results if *I*^2^ is larger than 50%. Otherwise, the authors used the Mantel-Haenszel method to pool the results. The authors also conducted subgroup analyses by type of diseases. The authors examined the stabilities of pooled meta-analysis results by omitting one study each time and pooling the results of the other studies. The authors examined publication biases by using funnel plots.

Results {#Sec6}
=======

Characteristics of included studies {#Sec7}
-----------------------------------

One hundred and thirty-two articles were retrieved by the authors through our literature searching strategy. The authors assessed 54 articles for eligibility after omitting unrelated and repeated reports. Twenty reviews were further excluded by the authors, and another three articles were also excluded by the authors due to the lack of crucial data. Totally, 31 studies were finally pooled in our meta-analyses (Fig. [1](#Fig1){ref-type="fig"}). Extracted data of eligible studies were summarized in Table [1](#Tab1){ref-type="table"}. Fig. 1Flowchart of study selection for the present studyTable 1The characteristics of included studies for this meta-analysisFirst author, yearCountryEthnicityType of diseaseSample sizeGenotypes (wtwt/wtmt/mtmt)*P* value for HWENOS scoreCasesControlsrs231775 A/G Cai 2011\*ChinaEast AsianEsophageal cancer125/25030/68/2770/133/470.2488 Cheng 2006\*TaiwanEast AsianGastric cancer62/25034/26/2119/102/290.3237 Cheng 2011\*ChinaEast AsianEsophageal cancer205/20554/105/4690/79/360.0137 Cozar 2007\*SpainCaucasianColorectal cancer96/17646/44/678/77/210.7668 Cui 2012\*ChinaEast AsianColorectal cancer128/20573/46/984/68/53\< 0.0017 Cui 2016\*ChinaEast AsianLiver cancer96/20552/37/764/96/450.4297 Dilmec 2008\*TurkeyMixedColorectal cancer56/16236/19/1108/43/110.0287 Fan 2012\*ChinaEast AsianColorectal cancer291/352123/146/22170/138/440.0598 Ge 2015\*ChinaEast AsianColorectal cancer572/626296/242/34292/284/500.0947 Gu 2010\*ChinaEast AsianLiver cancer367/407150/166/51183/179/450.9028 Hadinia 2007\*IranMixedColorectal cancer105/19052/47/6117/59/140.0978 Hadinia 2007\*IranMixedGastric cancer46/19027/13/6117/59/140.0978 Hou 2010\*ChinaEast AsianGastric cancer205/26294/70/41107/100/55\< 0.0017 Hu 2010\*ChinaEast AsianLiver cancer853/854367/380/106399/376/790.4768 Lang 2012\*ChinaEast AsianPancreatic cancer602/651208/312/82263/326/620.0068 Li 2011\*ChinaEast AsianColorectal cancer248/380120/120/8171/167/420.8988 Liu 2015\*ChinaEast AsianLiver cancer80/7829/36/1538/33/70.9667 Liu 2015\*ChinaEast AsianEsophageal cancer629/686307/254/43310/296/580.2847 Liu 2019\*ChinaEast AsianGastric cancer487/1470228/215/44698/631/1410.9267 Mahajan 2008\*PolandCaucasianGastric cancer301/41189/153/59152/189/700.3937 Qi 2010\*ChinaEast AsianColorectal cancer124/40760/60/4183/179/450.9028 Solerio 2005\*ItalyCaucasianColorectal cancer132/23876/43/13128/91/190.6188 Sun 2008\*ChinaEast AsianGastric cancer530/530235/235/60282/209/390.9748 Sun 2008\*ChinaEast AsianEsophageal cancer629/686307/254/43310/290/580.3988 Tang 2016\*ChinaEast AsianGastric cancer330/590155/153/22278/264/480.1798 Wang 2015\*ChinaEast AsianColorectal cancer311/389121/147/43141/147/101\< 0.0017 Yang 2012\*ChinaEast AsianPancreatic cancer368/926140/178/50482/374/700.8288 Yang 2015\*ChinaEast AsianColorectal cancer240/147195/39/6102/40/50.6627 Yang 2019\*ChinaEast AsianLiver cancer575/920290/221/64444/389/870.8938 Yuan 2012\*ChinaEast AsianGastric cancer118/9665/45/830/45/210.5957 Zou 2018\*ChinaEast AsianColorectal cancer979/1299417/443/119621/563/1150.4308rs4553808 A/G Cui 2016\*ChinaEast AsianLiver cancer96/20533/56/779/96/300.9247 Hadinia 2007\*IranMixedColorectal cancer109/18874/33/2145/36/70.027 Hadinia 2007\*IranMixedGastric cancer46/18837/9/0145/36/70.027 Hou 2010\*ChinaEast AsianGastric cancer205/262112/71/22163/54/45\< 0.0017rs5742909 C/T Cheng 2006\*TaiwanEast AsianGastric cancer62/25059/3/0209/40/10.3237 Dilmec 2008\*TurkeyMixedColorectal cancer56/16248/8/0149/12/10.1857 Hadinia 2007\*IranMixedGastric cancer46/18738/8/0159/24/40.0148 Hadinia 2007\*IranMixedColorectal cancer108/18791/16/1159/24/40.0137 Li 2009\*ChinaEast AsianGastric cancer236/121206/27/399/17/50.0017 Wang 2019\*ChinaEast AsianLiver cancer554/612360/170/24466/134/120.5178 Yang 2015\*ChinaEast AsianColorectal cancer240/147150/82/894/48/50.7077rs3087243 CT60AG Cheng 2006\*TaiwanEast AsianGastric cancer62/25039/20/3154/79/170.1267 Cozar 2007\*SpainCaucasianColorectal cancer95/17520/56/1940/88/470.9237 Ge 2015\*ChinaEast AsianColorectal cancer1699/6271258/425/16413/198/160.1748 Liu 2019\*ChinaEast AsianGastric cancer487/1472302/172/13958/462/520.6868 Tang 2016\*ChinaEast AsianGastric cancer316/580213/98/5382/182/160.3028 Wang 2019\*ChinaEast AsianLiver cancer554/612200/238/116240/274/980.1858 Yang 2019\*ChinaEast AsianLiver cancer575/921325/221/29609/282/300.7038 Zou 2018\*ChinaEast AsianColorectal cancer980/1300637/296/47850/408/420.4108rs733618 T/C Cui 2016\*ChinaEast AsianLiver cancer96/20572/24/0181/24/00.3737 Hadinia 2007\*IranMixedColorectal cancer109/18997/12/0165/24/00.3517 Hadinia 2007\*IranMixedGastric cancer83/18942/41/0165/24/00.3517 Hou 2010\*ChinaEast AsianGastric cancer205/26275/111/1993/139/300.0417 Liu 2019\*ChinaEast AsianGastric cancer487/1472168/242/77525/685/2620.1398 Tang 2014\*ChinaEast AsianEsophageal cancer611/657210/300/101228/314/1150.7008 Tang 2016\*ChinaEast AsianGastric cancer320/586102/163/55198/282/1060.7498 Yang 2019\*ChinaEast AsianLiver cancer575/921217/268/90320/432/1690.2758 Zou 2018\*ChinaEast AsianColorectal cancer980/1300346/464/170458/613/2290.3358rs16840252 C/T Liu 2019\*ChinaEast AsianGastric cancer492/1472381/94/71130/329/130.0398 Tang 2016\*ChinaEast AsianGastric cancer317/603235/78/4460/130/130.2938 Yang 2019\*ChinaEast AsianLiver cancer575/921477/93/5707/205/90.1648 Zou 2018\*ChinaEast AsianColorectal cancer980/1300742/223/151006/283/110.0658*Abbreviations*: *wt* wild type, *mt* mutant type, *HWE* Hardy-Weinberg equilibrium, *NOS* Newcastle-Ottawa scale, *NA* not available\*Full manuscript of all eligible studies can be accessed at <https://osf.io>

Meta-analysis results of CTLA-4 polymorphisms and digestive system malignancies {#Sec8}
-------------------------------------------------------------------------------

Twenty-eight studies were eligible for estimation of relationship between rs231775 polymorphism and digestive system malignancies, three studies were eligible for estimation of relationship between rs4553808 polymorphism and digestive system malignancies, six studies were eligible for estimation of relationship between rs5742909 polymorphism and digestive system malignancies, eight studies were eligible for estimation of relationship between rs3087243 polymorphism and digestive system malignancies, eight studies were eligible for estimation of relationship between rs733618 polymorphism and digestive system malignancies, and four studies were eligible for estimation of relationship between rs16840252 polymorphism and digestive system malignancies. *CTLA-4* rs231775 (over-dominant comparison: OR = 1.06, *p* = 0.03), rs4553808 (dominant comparison: OR = 0.77, *p* = 0.04; recessive comparison: OR = 0.52, *p* = 0.003; over-dominant comparison: OR = 1.73, *p* \< 0.0001), and rs733618 (over-dominant comparison: OR = 1.27, *p* = 0.04) polymorphisms were found to be significantly associated with digestive system malignancies in overall pooled meta-analyses. We also obtained positive findings for rs231775 polymorphism in colorectal cancer (recessive and over-dominant comparisons) and pancreatic cancer (dominant, recessive, over-dominant, and allele comparisons) subgroups, for rs4553808 polymorphism in gastric cancer (recessive and over-dominant comparisons) subgroup, for rs5742909 polymorphism in gastric cancer (dominant and allele comparisons) subgroup, for rs3087243 polymorphism in liver cancer (dominant, recessive, and allele comparisons) subgroup, and for rs733618 polymorphism in colorectal cancer (allele comparison) subgroup. Nevertheless, no any positive results were observed for rs16840252 polymorphism in pooled meta-analyses (see Table [2](#Tab2){ref-type="table"}). Table 2Meta-analysis results of this studyVariablesSample sizeDominant comparisonRecessive comparisonOver-dominant comparisonAllele comparisonM/M vs. M/m + m/mm/m vs. M/M + M/mM/m vs. M/M + m/mM vs. m*p* valueOR (95%CI)*p* valueOR (95%CI)*p* valueOR (95%CI)*p* valueOR (95%CI)rs231775 Overall9890/14,2380.910.99 (0.89--1.11)0.130.86 (0.71--1.05)*0.03*1.06 (1.00--1.12)0.221.06 (0.96--1.17) Esophageal cancer1588/18270.470.87 (0.60--1.26)0.710.96 (0.77--1.20)0.671.05 (0.83--1.35)0.570.93 (0.93--1.19) Gastric cancer2079/37990.841.02 (0.81--1.29)0.650.92 (0.66--1.30)0.271.07 (0.95--1.19)0.161.14 (0.95--1.37) Colorectal cancer3042/44240.641.04 (0.88--1.23)0.0070.55 (0.35--0.84)0.0061.14 (1.04--1.25)0.091.16 (0.98--1.38) Liver cancer1971/24640.821.04 (0.76--1.41)0.571.13 (0.75--1.70)0.410.95 (0.84--1.07)0.981.00 (0.77--1.31) Pancreatic cancer970/1577\< 0.00010.67 (0.57--0.79)0.00011.67 (1.29--2.16)0.031.20 (1.02--1.42)\< 0.00010.73 (0.64--0.82)rs4553808 Overall456/8430.040.77 (0.60--0.98)0.0030.52 (0.34--0.81)\< 0.00011.73 (1.34--2.24)0.870.98 (0.81--1.19) Gastric cancer251/4500.200.80 (0.57--1.12)0.030.56 (0.33--0.95)0.0021.77 (1.23--2.55)0.861.02 (0.78--1.34)rs5742909 Overall1302/16660.760.94 (0.63--1.40)0.421.22 (0.75--1.99)0.421.15 (0.82--1.62)0.580.87 (0.54--1.41) Gastric cancer344/5580.041.58 (1.01--2.48)0.140.40 (0.12--1.36)0.460.74 (0.33--1.66)0.011.69 (1.12--2.56) Colorectal cancer404/4960.450.88 (0.63--1.23)0.660.81 (0.32--2.08)0.331.19 (0.84--1.68)0.150.58 (0.28--1.21)rs3087243 Overall4768/59370.720.96 (0.79--1.17)0.660.92 (0.64--1.33)0.701.03 (0.87--1.23)0.900.99 (0.84--1.17) Gastric cancer865/23020.530.95 (0.81--1.12)0.140.69 (0.43--1.13)0.231.11 (0.94--1.31)0.951.00 (0.86--1.15) Colorectal cancer2774/21020.451.14 (0.81--1.59)0.490.75 (0.32--1.72)0.580.92 (0.69--1.23)0.391.15 (0.84--1.56) Liver cancer1129/1533*0.04*0.76 (0.58--0.99)0.0061.43 (1.11--1.85)0.511.15 (0.76--1.73)\< 0.00010.78 (0.69--0.88)rs733618 Overall3466/57810.100.81 (0.64--1.04)0.120.91 (0.80--1.02)0.041.27 (1.01--1.59)0.160.88 (0.74--1.05) Gastric cancer1095/25090.130.65 (0.37--1.14)0.230.88 (0.72--1.08)0.081.60 (0.95--2.70)0.180.77 (0.52--1.13) Colorectal cancer1089/14890.891.01 (0.85--1.20)0.870.98 (0.79--1.22)0.991.00 (0.85--1.18)0.050.89 (0.79--1.00) Liver cancer671/11260.500.70 (0.25--1.96)0.180.83 (0.62--1.09)0.381.50 (0.60--3.73)0.510.73 (0.29--1.85)rs16840252 Overall2364/42960.641.05 (0.85--1.31)0.940.99 (0.73--1.34)0.440.91 (0.72--1.16)0.891.01 (0.83--1.24) Gastric cancer809/20750.840.98 (0.81--1.19)0.191.22 (0.90--1.66)0.890.97 (0.68--1.40)0.390.93 (0.78--1.10)*Abbreviations*: *OR* odds ratio, *CI* confidence interval, *NA* not available

Sensitivity analyses {#Sec9}
--------------------

Stabilities of pooled meta-analysis results were examined by omitting one study each time and pooling the results of the other studies. The trends of associations remained unchanged in sensitivity analyses, indicating that our pooled meta-analysis results were statistically stable.

Publication biases {#Sec10}
------------------

Publication biases were examined by funnel plots. Funnel plots were overall symmetrical, suggesting that our pooled meta-analysis results were not likely to be severely influenced by publication biases.

Discussion {#Sec11}
==========

CTLA-4 is expressed on activated T cells, and it negatively regulates T cell activation and proliferation. Previous studies have demonstrated that CTLA-4 modulates the duration and strength of T cell-mediated immune responses by competitive binding with co-stimulating B7 molecules and activating of FAS-dependent apoptosis of T cells \[[@CR9], [@CR10]\]. Recently, abnormal expression of *CTLA-4* gene has been documented in many types of cancers, and it might contribute to cancer initiation and progression \[[@CR13]--[@CR15]\]. Considering that genetic polymorphisms might influence gene expression or even protein function, *CTLA-4* gene polymorphisms have also been extensively explored with regard to their relationships with different types of malignant disorders. In this meta-analysis, we summarized potential relationships between *CTLA-4* gene polymorphisms and digestive system malignancies by pooling the results of 31 related studies. Our pooled meta-analysis results demonstrated that rs231775 polymorphism was associated with predisposition to colorectal cancer and pancreatic cancer, rs4553808 and rs5742909 polymorphisms were associated with predisposition to gastric cancer, rs3087243 polymorphism was associated with predisposition to liver cancer, and rs733618 polymorphism was associated with predisposition to colorectal cancer. The trends of associations remained unchanged in sensitivity analyses, suggesting that our pooled meta-analysis results were quite statistically stable.

A few points should be considered when interpreting our findings. First, previous experimental studies demonstrated that all investigated polymorphisms might result in altered gene expression or protein structure of CTLA-4 \[[@CR16], [@CR17]\]. Thus, it is likely that these polymorphisms might also influence normal functioning of *CTLA-4*, give rise to immune dysfunction, jeopardize anti-tumor immune responses, and influence predisposition to malignancies, and this is the reason why we investigated these polymorphisms in this meta-analysis. Second, although we pooled the results of related studies, the sample size of many comparisons were still relatively small, so future genetic association studies with larger sample sizes are still needed to estimate the relationship between *CTLA-4* polymorphisms and different types of digestive system malignancies so as to get more statistically robust findings. Third, the etiologies and pathogenesis mechanisms of digestive system malignancies are extremely sophisticated, so further association studies also need to investigate the potential influence of gene-gene or gene-environmental interactions on predisposition to digestive system malignancies \[[@CR18]\]. Fourth, we aimed to investigate all *CTLA-4* polymorphisms at the beginning. However, we did not find sufficient eligible articles to support pooled meta-analyses of other *CTLA-4* polymorphisms, so we only examined six polymorphisms in this meta-analysis.

Like all meta-analyses, a few limitations of our pooled meta-analyses should also be acknowledged. Firstly, our pooled meta-analysis results were derived from pooling unadjusted findings because we did not have access to raw data of eligible studies \[[@CR19]\]. Secondly, environmental factors might also influence relationship between *CTLA-4* polymorphisms and digestive system malignancies. However, most investigators only focused on genetic associations in their works, so gene-environmental interactions were not explored in this meta-analysis \[[@CR20]\]. Thirdly, we did not search for grey literatures. Therefore, despite that funnel plots of pooled analyses were overall symmetrical, potential publication biases still might influence the robustness of our pooled results \[[@CR21]\].

Conclusion {#Sec12}
==========

So to conclude, this meta-analysis demonstrated that rs231775 polymorphism was associated with predisposition to colorectal cancer and pancreatic cancer, rs4553808 and rs5742909 polymorphisms were associated with predisposition to gastric cancer, rs3087243 polymorphism was associated with predisposition to liver cancer, and rs733618 polymorphism was associated with predisposition to colorectal cancer. These results indicated that these *CTLA-4* polymorphisms might have the potential to serve as genetic biomarkers of digestive system malignancies. Nevertheless, detailed functional analyses are still required to reveal the precise molecular mechanisms of the observed significant associations between *CTLA-4* polymorphisms and digestive system malignancies. Moreover, future studies should also test whether these *CTLA-4* polymorphisms can be used to detect digestive system malignancies in clinical practice.
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